ValuEngine downgraded shares of Misonix (NASDAQ:MSON) from a buy rating to a hold rating in a research report report published on Friday morning.
Other analysts have also recently issued reports about the company. Canaccord Genuity initiated coverage on Misonix in a research report on Friday, August 24th. They set a buy rating and a $24.00 price objective for the company. Craig Hallum initiated coverage on Misonix in a research report on Tuesday, September 11th. They set a buy rating and a $28.00 price objective for the company. Finally, TheStreet cut Misonix from a c rating to a d+ rating in a research report on Friday, September 7th.
Shares of NASDAQ MSON remained flat at $$16.50 during trading hours on Friday. The company had a trading volume of 10,918 shares, compared to its average volume of 19,555. Misonix has a 1 year low of $8.25 and a 1 year high of $21.43.
Misonix (NASDAQ:MSON) last posted its quarterly earnings data on Thursday, November 8th. The medical equipment provider reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). Misonix had a negative return on equity of 14.05% and a negative net margin of 23.24%. The company had revenue of $9.36 million for the quarter.
In other Misonix news, VP Christopher H. Wright sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $16.31, for a total transaction of $163,100.00. Following the completion of the sale, the vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $163,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Joseph J. Brennan sold 8,357 shares of the stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $15.91, for a total value of $132,959.87. Following the sale, the vice president now directly owns 5,649 shares of the company’s stock, valued at $89,875.59. The disclosure for this sale can be found here. Insiders have sold a total of 18,958 shares of company stock valued at $305,838 over the last ninety days. 24.60% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Misonix by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock worth $3,941,000 after buying an additional 28,889 shares in the last quarter. Nordea Investment Management AB purchased a new position in shares of Misonix during the 3rd quarter worth approximately $649,000. Manatuck Hill Partners LLC purchased a new position in shares of Misonix during the 3rd quarter worth approximately $329,000. Renaissance Technologies LLC raised its stake in shares of Misonix by 10.8% during the 3rd quarter. Renaissance Technologies LLC now owns 231,899 shares of the medical equipment provider’s stock worth $4,290,000 after buying an additional 22,599 shares in the last quarter. Finally, Bridgeway Capital Management Inc. raised its stake in shares of Misonix by 24.3% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 68,100 shares of the medical equipment provider’s stock worth $1,260,000 after buying an additional 13,300 shares in the last quarter. 15.93% of the stock is owned by institutional investors.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Further Reading: What is a capital gain?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.